No Data
No Data
Hongbo Pharmaceutical (301230.SZ): Dingtai Haifu's shareholding ratio fell below 5%
Gelonghui, May 24, 丨 Hongbo Pharmaceutical (301230.SZ) announced that the company recently received the “Simplified Equity Change Report” issued by Dingtai Haifu. On May 24, 2024, Dingtai Haifu reduced its holdings of the company's shares through centralized bidding, accounting for 0.0517% of the company's total share capital. After this equity change, the total number of shares held by Dingtai Haifu decreased to 5,381,066 shares. The shareholding ratio dropped to 4.9999%, no longer holding 5% or more of the company's shares.
Pacific Securities: The pharmaceutical industry is under short-term pressure, and future policies will be frequent or enhance the certainty of clinical CRO benefits
With the end of the Fed's interest rate hike cycle, gradual easing of liquidity is expected to bring about a recovery in investment and financing, and overseas demand will improve ahead of local demand; future innovative drug support policies may be introduced intensively, and clinical CRO benefits are highly certain.
Hongbo Pharmaceutical (301230.SZ): A total cost of 178.587 million yuan to buy back 629,300 shares
Gelonghui, May 7, 丨 Hongbo Pharmaceutical (301230.SZ) announced that as of April 30, 2024, the company had repurchased 629,300 shares through a dedicated securities account, accounting for 0.5847% of the company's current total share capital of 107,622,666 shares. The highest transaction price was 37.68 yuan/share, and the lowest transaction price was 26.82 yuan/share. The total transaction amount was 178.587 million yuan (excluding transaction fees).
Zhongfu Cornerstone, a shareholder of Hongbo Pharmaceutical (301230.SZ), reduced its holdings by a total of 1.074,800 shares
Hongbo Pharmaceutical (301230.SZ) announced that the company's shareholder Zhongfu Cornerstone's holdings reduction plan has been implemented. Zhongfu Ji...
Hongbo Pharmaceutical (301230.SZ): Net profit of 3.667,700 yuan in the first quarter decreased by 75.99% year-on-year
On April 25, Ge Longhui Pharmaceutical (301230.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 131 million yuan, up 7.69% year on year; net profit attributable to shareholders of listed companies was 36.677 million yuan, down 75.99% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 625,500 yuan, down 95.45% year on year; basic earnings per share were 0.03 yuan.
The Price Is Right For PharmaResources (Shanghai) Co., Ltd. (SZSE:301230) Even After Diving 26%
PharmaResources (Shanghai) Co., Ltd. (SZSE:301230) shareholders won't be pleased to see that the share price has had a very rough month, dropping 26% and undoing the prior period's positive performanc
No Data